PRIMROSE Audit: A multicentre audit of care provided to patients with breast cancer involving the brain in the UK

PRIMROSE Audit: A Prospective Multi-Centre Project to Assess the Presentation, Management, and Outcomes of Patients with CNS Disease Secondary to Breast Cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN18204314

Enrollment

100

Registered

2020-08-19

Start date

2020-08-01

Completion date

Unknown

Last updated

2020-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Nervous System disease secondary to breast cancer Cancer

Interventions

Patients' records will be reviewed to collect routine care data on demographic information, clinicopathological features and treatment of primary breast cancer, information relating to disease recurre

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. =16 years of age 2. Histologically and/or cytologically confirmed breast cancer with CNS involvement, as defined as having one or more of the following: 2.1. Metastases to the brain parenchyma 2.2. Metastases to the leptomeninges 2.3. Paraneoplastic Neurological Disorders

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
Overall survival from initial diagnosis of CNS involvement secondary breast cancer measured using patient records at a single time point.	—

Secondary

Measure	Time frame
Measured at a single time point: 1. Number of cases of metastatic breast cancer involving the CNS presenting in UK centres per year measured using patient records 2. Current practice in UK centres regarding the diagnosis and management of CNS disease secondary to breast cancer in relation to national and international guidelines: 2.1. Prior cancer treatment for non-CNS metastatic disease 2.2. Surgical and radiotherapy treatment of CNS disease 2.3. Current anti-cancer treatment and concomitant medications 3. Outcomes of patients treated for CNS involvement secondary to breast cancer in UK centres: 3.1. Time to progression from surgery, radiotherapy or systemic therapy, defined as time from commencement of treatment for CNS disease to disease progression and site of progression 3.2. Overall survival measured as the time from diagnosis of recurrent disease until death of any cause 3.3. Cause of death: Progressive CNS disease versus progressive disease at other sites	—

Measure

Time frame

Measured at a single time point: 1. Number of cases of metastatic breast cancer involving the CNS presenting in UK centres per year measured using patient records 2. Current practice in UK centres regarding the diagnosis and management of CNS disease secondary to breast cancer in relation to national and international guidelines: 2.1. Prior cancer treatment for non-CNS metastatic disease 2.2. Surgical and radiotherapy treatment of CNS disease 2.3. Current anti-cancer treatment and concomitant medications 3. Outcomes of patients treated for CNS involvement secondary to breast cancer in UK centres: 3.1. Time to progression from surgery, radiotherapy or systemic therapy, defined as time from commencement of treatment for CNS disease to disease progression and site of progression 3.2. Overall survival measured as the time from diagnosis of recurrent disease until death of any cause 3.3. Cause of death: Progressive CNS disease versus progressive disease at other sites

—

Countries

United Kingdom

Contacts

Public ContactCarlo Palmieri

c.palmieri@liv.ac.uk+44 (0)151 706 3616

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026